FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1236342233> ?p ?o ?g. }

• W1236342233 endingPage "1090" @default.
• W1236342233 startingPage "1073" @default.
• W1236342233 abstract "Based upon the rather large worldwide experience that has been published recently, it would appear that the concept of subacute cutaneous LE as presented in our original reports starting 10 years ago is still a viable one. However, we must now also consider the possibility that these patients will occasionally develop other types of autoimmune disorders such as rheumatoid arthritis and Sjögren's syndrome and, on occasion, have their skin disease triggered by drugs such as hydrochlorothiazide. However, the majority of these patients will have recurrent skin disease activity and musculoskeletal symptoms as the major manifestations of their illness. Although most of these patients do have a relatively mild disease course, a small percentage seem to be at risk for developing potentially life-threatening complications of systemic LE. The future challenge in this area lies in identifying prognostic features that may correlate with this more aggressive disease course so that this subgroup of patients can be more efficiently managed. Our preliminary studies have suggested several candidates for further study: the papulosquamous/psoriasiform subacute cutaneous LE lesional subtype; development of acute cutaneous LE; resistance to antimalarials alone; leukopenia; high titer ANA; and the presence of circulating double-stranded DNA antibodies. Another possibility may include the rate of systemic disease onset. Discoid LE patients who have not developed clinically significant SLE manifestations within the first 2 years of the appearance of their skin lesions have a very low risk for suffering from severe SLE complications later in their disease course. The same question might be asked of subacute cutaneous LE. In addition, some subacute cutaneous LE patients have a single episode of disease activity followed by long-term, if not permanent, remission. More needs to be learned about this more benign pattern of illness in the hope of identifying favorable prognostic signs. Our impressions regarding subacute cutaneous LE disease outcome have mostly come from retrospective or point-prevalence types of clinical analyses; more prospective examinations of large groups of patients will be required to better address the issue of prognosis in subacute cutaneous LE. The data published to date suggest that this is a relatively homogeneous group of patients immunogenetically: they frequently have circulating anti-Ro auto-antibodies and often possess the HLA-DR3 phenotype. Much circumstantial evidence indicates that this particular genetically determined autoimmune response might be directly participating in pathogenesis of this form of LE-specific skin injury.(ABSTRACT TRUNCATED AT 400 WORDS)" @default.
• W1236342233 created "2016-06-24" @default.
• W1236342233 creator A5014463694 @default.
• W1236342233 date "1989-09-01" @default.
• W1236342233 modified "2023-10-18" @default.
• W1236342233 title "Subacute Cutaneous Lupus Erythematosus: A Decade’s Perspective" @default.
• W1236342233 cites W1554660758 @default.
• W1236342233 cites W1560319441 @default.
• W1236342233 cites W1975861371 @default.
• W1236342233 cites W1976323831 @default.
• W1236342233 cites W1978169549 @default.
• W1236342233 cites W1986738182 @default.
• W1236342233 cites W1988135325 @default.
• W1236342233 cites W1992283958 @default.
• W1236342233 cites W1997585785 @default.
• W1236342233 cites W1997727393 @default.
• W1236342233 cites W1998743172 @default.
• W1236342233 cites W2004298720 @default.
• W1236342233 cites W2004989086 @default.
• W1236342233 cites W2005286533 @default.
• W1236342233 cites W2012552244 @default.
• W1236342233 cites W2017718359 @default.
• W1236342233 cites W2029200225 @default.
• W1236342233 cites W2034490386 @default.
• W1236342233 cites W2036603484 @default.
• W1236342233 cites W2036999245 @default.
• W1236342233 cites W2043344763 @default.
• W1236342233 cites W2045304841 @default.
• W1236342233 cites W2048375132 @default.
• W1236342233 cites W2049311571 @default.
• W1236342233 cites W2064249573 @default.
• W1236342233 cites W2064283640 @default.
• W1236342233 cites W2067528827 @default.
• W1236342233 cites W2069722650 @default.
• W1236342233 cites W2070618191 @default.
• W1236342233 cites W2082314813 @default.
• W1236342233 cites W2086037537 @default.
• W1236342233 cites W2095977051 @default.
• W1236342233 cites W2099431441 @default.
• W1236342233 cites W2101365513 @default.
• W1236342233 cites W2114414879 @default.
• W1236342233 cites W2120601664 @default.
• W1236342233 cites W2122460044 @default.
• W1236342233 cites W2151412783 @default.
• W1236342233 cites W2160268607 @default.
• W1236342233 cites W2170788135 @default.
• W1236342233 cites W4253185158 @default.
• W1236342233 cites W4298289326 @default.
• W1236342233 cites W4318357348 @default.
• W1236342233 cites W4323238912 @default.
• W1236342233 doi "https://doi.org/10.1016/s0025-7125(16)30620-4" @default.
• W1236342233 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2671533" @default.
• W1236342233 hasPublicationYear "1989" @default.
• W1236342233 type Work @default.
• W1236342233 sameAs 1236342233 @default.
• W1236342233 citedByCount "150" @default.
• W1236342233 countsByYear W12363422332012 @default.
• W1236342233 countsByYear W12363422332013 @default.
• W1236342233 countsByYear W12363422332015 @default.
• W1236342233 countsByYear W12363422332016 @default.
• W1236342233 countsByYear W12363422332017 @default.
• W1236342233 countsByYear W12363422332018 @default.
• W1236342233 countsByYear W12363422332019 @default.
• W1236342233 countsByYear W12363422332020 @default.
• W1236342233 countsByYear W12363422332021 @default.
• W1236342233 countsByYear W12363422332022 @default.
• W1236342233 countsByYear W12363422332023 @default.
• W1236342233 crossrefType "journal-article" @default.
• W1236342233 hasAuthorship W1236342233A5014463694 @default.
• W1236342233 hasConcept C126322002 @default.
• W1236342233 hasConcept C159654299 @default.
• W1236342233 hasConcept C16005928 @default.
• W1236342233 hasConcept C203014093 @default.
• W1236342233 hasConcept C2775915377 @default.
• W1236342233 hasConcept C2776670291 @default.
• W1236342233 hasConcept C2776694085 @default.
• W1236342233 hasConcept C2776912625 @default.
• W1236342233 hasConcept C2777575956 @default.
• W1236342233 hasConcept C2777761306 @default.
• W1236342233 hasConcept C2778674544 @default.
• W1236342233 hasConcept C2779075594 @default.
• W1236342233 hasConcept C2779134260 @default.
• W1236342233 hasConcept C2780564577 @default.
• W1236342233 hasConcept C2780873365 @default.
• W1236342233 hasConcept C71924100 @default.
• W1236342233 hasConceptScore W1236342233C126322002 @default.
• W1236342233 hasConceptScore W1236342233C159654299 @default.
• W1236342233 hasConceptScore W1236342233C16005928 @default.
• W1236342233 hasConceptScore W1236342233C203014093 @default.
• W1236342233 hasConceptScore W1236342233C2775915377 @default.
• W1236342233 hasConceptScore W1236342233C2776670291 @default.
• W1236342233 hasConceptScore W1236342233C2776694085 @default.
• W1236342233 hasConceptScore W1236342233C2776912625 @default.
• W1236342233 hasConceptScore W1236342233C2777575956 @default.
• W1236342233 hasConceptScore W1236342233C2777761306 @default.
• W1236342233 hasConceptScore W1236342233C2778674544 @default.
• W1236342233 hasConceptScore W1236342233C2779075594 @default.
• W1236342233 hasConceptScore W1236342233C2779134260 @default.

• next